KLTO (Klotho Neurosciences) Capex-to-Revenue : 0.00 (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Klotho Neurosciences Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Klotho Neurosciences's Capital Expenditure for the three months ended in Dec. 2024 was $0.00 Mil. Its Revenue for the three months ended in Dec. 2024 was $0.00 Mil.

GuruFocus do not calculate Capex-to-Revenue if the revenue is negative.

Klotho Neurosciences Capex-to-Revenue Historical Data

The historical data trend for Klotho Neurosciences's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Klotho Neurosciences Capex-to-Revenue Chart

Klotho Neurosciences Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Capex-to-Revenue

Klotho Neurosciences Quarterly Data
	Dec21	Jun22	Dec22	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Capex-to-Revenue	Get a 7-Day Free Trial					-	-	-	-	-

Competitive Comparison of Klotho Neurosciences's Capex-to-Revenue

For the Biotechnology subindustry, Klotho Neurosciences's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Klotho Neurosciences's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Klotho Neurosciences's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Klotho Neurosciences's Capex-to-Revenue falls into.

Save Embed

;

Save Embed

;

Klotho Neurosciences Capex-to-Revenue Calculation

Klotho Neurosciences's Capex-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (-0.123)	/	0
	=	N/A

Klotho Neurosciences's Capex-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (0)	/	0
	=	N/A

Klotho Neurosciences (NAS:KLTO) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.

Klotho Neurosciences Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Klotho Neurosciences's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Klotho Neurosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Klotho Neurosciences Inc (NAS:KLTO) » Definitions » Capex-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

13576 Walnut Street, Suite A, Omaha, NE, USA, 68144

Website

https://www.klothoneuro.com

Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.